You are here
SHIFA BIOMEDICAL CORPORATION
UEI: J3TLJQ7LFK49
# of Employees: 3
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Oral PCSK9/LDLR antagonist direction to the clinic
Amount: $1,889,288.00Project Summary/Abstract Heart disease has been the leading cause of death in the United States and the world for more than a century, ever since the early 1900s. About 610,000 people die of heart dis ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Improving Solubility, Stability and Permeability of Natural Products Extracts
Amount: $286,946.00Project Summary Abstract Despite substantial developments of extraction and separation techniquesisolation of natural products from various sources is still a challenging taskand lead generation or va ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Development of Oral Small Molecule PCSK9 Antagonist
Amount: $1,348,901.00Project Summary AbstractThe epidemic of cardiovascular diseaseCVDis a global phenomenon that remains the number one cause of death throughout the worldkilling nearlymillion people per yeara number tha ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Novel Modulators of LDL Metabolism
Amount: $1,000,000.00DESCRIPTION provided by applicant Heart disease is the leading cause of death for both men and women in the US accounting for nearly of all annual deaths A high cholesterol level is well know ...
SBIRPhase II2014Department of Health and Human Services National Institutes of Health -
Novel Modulators of HDL Metabolism
Amount: $1,539,615.00Project Summary/Abstract Cardiovascular disease remains the leading cause of morbidity and mortality for both men and women, accounting for nearly 40% of annual deaths. High levels of LDL-C and low l ...
SBIRPhase II2012Department of Health and Human Services National Institutes of Health -
A Novel Cassette System for the Assembly of VLP Vaccines
Amount: $296,731.00DESCRIPTION (provided by applicant): Influenza and other infectious diseases are a major cause of death in the US and world-wide. Vaccination is the most cost-effective strategy to prevent these disea ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Novel Self-Limiting Prothrombinase Inhibitors
Amount: $347,218.00Project Summary/Abstract Thrombosis is a primary cause of death in the US and developed world. Fatal or debilitating blood clots occur in the three major diseases of the western world: heart attacks, ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Structure-Based Search for Novel Antihypercholestrolemic Agent
Amount: $1,336,680.00DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is well-know ...
SBIRPhase II2010Department of Health and Human Services National Institutes of Health -
Structure-Based Design of Novel HNF4a Antagonists to Treat Metabolic Syndrome
Amount: $290,230.00DESCRIPTION (provided by applicant): The long-term goal of this work is to develop novel drugs for the treatment of metabolic syndrome (MetS). MetS is an assemblage of associated clinical disorders re ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Novel Modulators of LDL Metabolism
Amount: $258,591.00DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is a well-kn ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health